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Abstract
The  biological  changes  that  commonly  cause  degenerative  articular  cartilage  injuries  in  the
knee are  primarily  associated  with  misalignment  of  the  joint  and  metabolic  changes  related
to age,  as  occurs  in  osteoarthritis.  Furthermore,  the  capacity  for  cartilage  self-regeneration  is
quite limited  due  to  the  lack  of  vascularity  of  the  tissue.  To  date,  there  is  no  ideal  treatment
capable  to  stimulate  cartilage  regeneration;  thus  there  is  a  need  to  seek  alternative  therapies
for the  treatment  of  such  conditions.
The  number  of  publications  demonstrating  the  therapeutic  and  regenerative  beneﬁts  of  using
platelet-rich  plasma  as  a  treatment  for  knee  osteoarthritis  has  been  increasing  in  recent  years.
In spite  of  encouraging  results,  there  are  still  only  a  few  randomised  control  studies  with  strong
clinical evidence,  lacking  clarity  on  points  such  as  the  optimum  formulation  or  the  mechanism
of action  of  platelet-rich  plasma.  Up  to  this  point  and  based  on  the  results  of  clinical  studies,
not all  patients  can  beneﬁt  from  this  therapy.  It  is  important  to  consider  aspects  such  as  the
age and  grade  of  cartilage  degeneration.
The  aim  of  the  present  paper  is  to  review  the  recent  scientiﬁc  literature  on  the  treatment  of
knee osteoarthritis  with  platelet-rich  plasma,  and  the  biological  bases  of  this  therapy,  as  well
as presenting  the  current  opinion  on  this  subject.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
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El  plasma  rico  en  plaquetas  en  osteoartrosis  de  rodilla:  una  alternativa  de
tratamiento.  Artículo  de  revisión
Resumen
Los  cambios  biológicos  degenerativos  que  frecuentemente  generan  lesiones  en  el  cartílago  artic-
ular de  rodilla  se  asocian  principalmente  con  defectos  en  la  alineación  de  la  articulación,  y  con
cambios de  tipo  metabólico  relacionados  con  la  edad  como  ocurre  en  la  osteoartrosis.  Además,
la capacidad  de  autorregeneración  del  cartílago  se  ve  bastante  limitada  debido  a  la  falta  de
vascularización  del  tejido.  Hasta  la  fecha  no  se  cuenta  con  un  tratamiento  ideal  que  logre  estim-
ular la  regeneración  del  cartílago,  por  lo  que  es  necesario  buscar  alternativas  terapéuticas  para
el tratamiento  de  este  tipo  de  padecimientos.
En an˜os  recientes  se  ha  incrementado  el  número  de  publicaciones  que  intentan  mostrar  los
beneﬁcios terapéuticos  y  regenerativos  al  utilizar  plasma  rico  en  plaquetas  como  tratamiento  en
osteoartrosis  de  rodilla.  A  pesar  de  los  resultados  alentadores  que  se  han  observado,  son  todavía
pocos los  estudios  controlados  aleatorizados,  con  evidencia  clínica  contundente,  quedando  por
esclarecer puntos  como  la  formulación  óptima  o  el  mecanismo  de  acción  del  plasma  rico  en
plaquetas. Hasta  este  punto,  no  todos  los  pacientes  pueden  tener  un  beneﬁcio  de  esta  terapia,
basándonos  en  los  resultados  de  los  estudios  clínicos,  en  donde  es  importante  tener  en  cuenta
aspectos como  la  edad  y  el  grado  de  desgaste  del  cartílago.
El objetivo  del  presente  trabajo  es  hacer  una  revisión  de  la  literatura  cientíﬁca  reciente,  del
tratamiento  de  la  osteoartrosis  de  rodilla  con  plasma  rico  en  plaquetas  y  de  las  bases  biológicas
de esta  terapia,  así  como  mostrar  una  opinión  actual  acerca  de  este  tema.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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Background
The  articular  cartilage  is  a  highly  specialised  connective  tis-
sue  in  mobile  joints,  whose  main  function  is  to  provide  an
articular  surface  with  low  friction  and  efﬁcient  support  for
mechanical  loads.  It  is  a  tissue  that  is  devoid  of  blood  ves-
sels,  lymphatic  vessels  and  nerve  endings,  so  its  intrinsic
regenerative  ability  is  very  low.1 The  lesions  caused  in  this
type  of  tissue  are  difﬁcult  to  treat  and  they  still  pose  a
challenge  today  in  the  orthopaedic  ﬁeld.
Biological  changes,  including  biomechanical  and
metabolic  ones,  as  well  as  traumas,  can  lead  to  a  loss  in
cartilage  homeostasis,  which  signiﬁcantly  increases  with
age.  This  results  in  an  accelerated  reduction  of  the  articular
surface,  which  causes  osteoarthrosis.2
This  is  the  most  frequent  chronic  and  degenerative  artic-
ular  disease,  the  most  common  source  of  pain  and  one  of
the  main  causes  of  disability  and  dependence  among  the
adult  population,  and  generates  high  costs  in  healthcare.3
Osteoarthrosis  is  more  common  in  females  (2:1),  although
after  menopause  the  male:female  ratio  is  1:1.  Its  frequency
increases  with  age,  so  according  to  radiographic  criteria,
30%  of  the  population  between  the  age  of  45  and  60  years
and  over  80%  of  people  over  the  age  of  80  years  have
osteoarthrosis  in  at  least  one  joint.4 Worldwide,  it  is  the
fourth  cause  of  morbidity  in  women  over  the  age  of  60  and
the  eighth  cause  in  men.5 In  Mexico,  a  10.5%  predominance
of  osteoarthrosis  has  been  estimated.6 According  to  the  sta-
tistical  reports  from  the  Instituto  Mexicano  de  Seguro  Social,
osteoarthrosis  is  one  of  the  ten  main  reasons  for  consulta-
tions  in  primary  healthcare.4
Clinically,  this  disease  is  characterised  by  joint  pain,  stiff-
ness,  motion  restriction  and  variable  degrees  of  swelling.7 It
w
cs  also  characterised  by  an  imbalance  between  anabolic  and
atabolic  processes,8 which  leads  to  progressive  damage  of
he  cartilage,  and  ultimately  to  the  patient’s  disability.
Treatments  for  osteoarthrosis  range  of  techniques  that
nly  relieve  pain,  such  as  arthroscopy  and  an  initial  pharma-
ological  treatment  with  analgesics  and  anti-inﬂammatory
rugs,  to  procedures  that  involve  the  creation  of  grafts  with
hree-dimensional  structures  in  the  tissue  engineering  ﬁeld.
owever,  up  to  this  moment,  there  is  no  effective  method
f  regenerating  cartilage.
In recent  years,  the  use  of  autologous  growth  factors
s  a  regenerative  treatment  for  chondral  tissue  has  been
aken  into  consideration  as  a  therapeutic  alternative.  These
rowth  factors  can  be  obtained  from  circulating  platelets
n  peripheral  blood.  Thus,  platelet-rich  plasma  therapy  has
ained  great  importance  in  the  last  few  years,  and  has
een  the  object  of  several  studies  and  efforts.  Its  use  in
issue  regeneration  has  spread  from  its  implementation  in
entistry,  maxillofacial  surgery  and  dental  implants,  the
egeneration  of  tendons  and  ligaments  in  orthopaedics,  to
ts  implementation  in  plastic  surgery  and  cosmetology.9
The  clinical  use  of  platelet-rich  plasma  has  been
roposed  as  a  therapeutic  alternative  in  patients  with
steoarthrosis,  administering  it  by  means  of  intra-articular
njections  directly  in  the  knees  of  the  affected  patients.
ost  of  the  studies  performed  so  far  show  promising  results,
ith  pain  reduction  and  an  improvement  in  joint  function.
 couple  of  years  ago,  studies  on  controlled  randomised  tri-
ls  began  to  be  published.  These  provided  improved  clinical
vidence  about  the  ﬁrst  non-controlled  trials  or  the  ones  in
hich  series  of  cases  were  analysed.
Proliferative  properties  have  also  been  reported10 of
hondrogenic11 and  anabolic  differentiation  in  platelet-rich
3p
i
t
o
W
T
t
p
c
A
3
d
t
b
e
a
o
a
p
w
r
t
E
A
p
s
i
i
s
a
p
c
s
o
p
p
t
i
c
e
m
a
t
s
p
b
c
t
i
i
r
r
F
T
a
a
l
(
u
p
ﬁ
f
a
p
i
w
i
i
g
m
n
I
p
i
G
G
a
T
a54  
lasma12 in  in  vitro  studies,  at  cellular  culture  level  and
n  in  vivo  studies,  mainly  in  mice  and  rabbits,  emphasising
he  role  of  platelet-rich  plasma  in  the  regeneration  of  the
steoathrotic  cartilage.
hat is  platelet-rich plasma?
his  is  a  preparation  that  has  a  higher  amount  of  platelets
han  normal  blood  levels.  In  most  cases,  platelet-rich
lasma  is  solely  deﬁned  according  to  the  absolute  platelet
ount,  and  not  according  to  other  blood  components.
 normal  platelet  blood  count  ranges  from  150,000  to
50,000  platelets/L, whereas  platelet-rich  plasma  is  often
eﬁned  as  a  concentration  that  is  two  or  four  times  higher
han  the  normal  concentration.13 Platelet-rich  plasma  can
e  obtained  and  elaborated  from  an  individual’s  periph-
ral  venous  blood,  after  one  or  two  centrifugation  steps
nd  using  basic  laboratory  material  or  equipment.  This  type
f  extract  represents  a  natural  source  of  growth  factors  of
utologous  origin,  which  is  one  of  its  main  properties.
The  logic  behind  the  use  of  platelet-rich  plasma  is  that
latelets  are  the  ﬁrst  component  that  acts  in  the  location
here  the  tissue  is  damaged,  so  they  have  the  ability  to
elease,  together  with  other  active  molecules,  growth  fac-
ors  that  play  an  essential  role  in  the  healing  process.14
laboration of platelet-rich plasma
mong  the  controversial  subjects  surrounding  platelet-rich
lasma,  the  lack  of  consensus  regarding  its  precise  compo-
ition  and  the  different  techniques  available  to  elaborate
t  stand  out.  These  can  be  classiﬁed  as  closed  techniques,
n  which  disposable  commercial  cases  are  used,  where  the
ample  is  treated  inside  just  one  container  (tube  or  syringe),
nd  open  techniques,  where  the  elaboration  of  platelet-rich
lasma  is  performed  manually  in  more  than  one  tube.  In  both
ases,  the  elaboration  involves  one  or  more  centrifugation
teps.
There  are  at  least  16  different  commercial  cases  to  elab-
rate  platelet-rich  plasma,  which  can  signiﬁcantly  vary  in
latelet,  leucocyte  and  erythrocyte  quantities  of  the  ﬁnal
roduct.15 Platelet  concentration  can  increase  up  to  9.3
imes  in  association  to  baseline  levels.16 On  the  other  hand,
n  a  manual  process  with  double  centrifugation,  platelet
oncentration  can  increase  up  to  330%,  which  would  be
qual  to  3.3  times.17
All  available  techniques  have  several  features  in  com-
on.  The  patient’s  blood  is  collected  in  tubes  with
c
w
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Table  1  Main  effects  on  chondrocytes  or  cartilage  of  some  growt
Growth  factor  Effect  on  chondrocy
Transforming  growth  factor-  (TGF-)  It  stimulates  the  syn
(proteoglycans,  type
Insulin-like  growth  factor  1  (IGF-1)  It  stimulates  the  syn
collagen.  It  reduces
Fibroblast  growth  factor-2  (FGF-2)  It  acts  as  a  mitogen  
chondrocytes)
Platelet-derived  growth  factor  (PDGF)  Increase  in  cellular  M.A.  Simental-Mendía  et  al.
nticoagulant  and  immediately  centrifuged.  This  initial  cen-
rifugation  separates  red  blood  cells  from  plasma.  The
eparated  plasma  can  contain  several  concentrations  of
latelets  with  or  without  white  blood  cells.  Platelets  can
e  activated  afterwards  using  thrombin,  calcium  chloride,
alcium  gluconate,  by  freezing  and  unfreezing  it,  and  then
his  is  applied  in  the  lesion  area  when  it  is  still  liquid  as  an
njection.  The  procedure  can  be  carried  out  in  a  minimally
nvasive  and  ambulatory  way,  providing  an  activated  prepa-
ation  directly  in  the  damaged  place  with  an  immediate
elease  of  the  growth  factors.
ormulation of platelet-rich plasma
here  can  be  approximately  1500  proteins  in  platelets,
mong  which  there  may  be  a few  growth  factors.18 Platelets
re  non-nucleated  cells  that  contain  different  intracellu-
ar  structures,  such  as  glycogen,  lysosomes  and  granules
dense  and  alpha),  to  mention  just  a few.19 In  partic-
lar,  alpha  granules  store  and  secrete  several  types  of
roteins,  such  as  adhesion  proteins,  coagulation  factors,
brinolytic  factors,  proteases  and  antiproteases,  growth
actors,  cytokines,  chemokines,  membrane  glycoproteins
nd  antimicrobial  proteins,  among  others.20
It  has  already  been  observed  that  some  of  the  bioactive
roteins  that  platelets  release  are  responsible  for  attract-
ng  macrophages,  mesenchymal  stem  cells  and  osteoblasts,
hich  not  only  facilitate  the  removal  of  necrotic  tissue
nside  the  lesion,  but  also  participate  in  advanced  biolog-
cal  functions  that  range  from  healing  wounds  to  tumour
rowth.21
The  fact  that  platelets  secrete  growth  factors  and  active
etabolites  can  have  a  positive  inﬂuence  in  clinical  sce-
arios  that  require  quick  healing  and  tissue  regeneration.
n  addition,  the  existence  of  growth  factors  connected  to
latelets  and/or  within  ﬁbrin  structures  can  result  in  an
mproved  activity  regarding  soluble  recombinant  proteins.22
rowth factors in platelet-rich plasma
rowth  factors  are  soluble  and  diffusible  macromolecules
nd  are  generated  by  a  great  variety  of  cellular  types.
hey  have  speciﬁc  actions  on  the  growth,  differentiation
nd  phenotype  of  numerous  types  of  cells,  among  which  are
hondrocytes.
These  molecules  interact  with  membrane  cell  receptors,
hich  transmit  signals  to  the  inside  of  the  cell  and  gener-
te  a  cascade  reaction  that  concludes  in  the  regulation  of
h  factors  found  in  platelet-rich  plasma.
tes/cartilage  Reference
thesis  of  extracellular  matrix
 II  collagen)
24
thesis  of  proteoglycans  and  type  II
 the  amount  of  type  I collagen
25,26
(it  stimulates  the  proliferation  of 27
proliferation  and  proteoglycan  production  28
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Table  2  Clinical  trials  on  the  administration  of  platelet-rich  plasma  therapy  in  knee  osteoarthrosis.
Author  and  reference  Type  of  study  Clinical  assessment
follow-up
Treatment
(number  of
patients)
Results  obtained
Sanchez  et  al.  (2008)36 Retrospective
comparative
WOMAC
(5  weeks)
PRGF  (30)  vs.  HA
(30)
Reduction  in  the  WOMAC
scale  attributed  to
treatment  with  PRP
(p  <  0.01)
Kon E  et  al.  (2010)37 Series  of  cases  IKDC
VAS
(6  and  12  months)
PRP  (91)  Signiﬁcant  improvement  of
clinical  evaluations
(p <  0.0005).  Improvements
decreased  after  12  months
Filardo et  al.  (2011)38 Series  of  cases
(PRP)
IKDC
VAS
(24  months)
PRP  (91)  Reduction  of  the
improvement  obtained
after  one-year  follow-up.
Results  were  better  than
prior  treatment  (p  <  0.0005)
Kon et  al.  (2011)39 Prospective
comparative
IKDC
VAS
(2  and  6  months)
PRP  (50)  vs.  LW  HA
(50)  vs.  HW  HA
(50)
Greater  efﬁcacy  and
durability  in  pain  reduction
and  recuperation  of  joint
function  with  PRP
(p  =  0.003  vs.  LW  HA;
p =  0.005  vs.  HW  HA)
Wang-Saegusa  et  al.
(2011)3
Series  of  cases  WOMAC
VAS
SF-36
(6  months)
PRP  (261)  Improvement  in  the
function  (p  <  0.0001),
quality  of  life  (p  <  0.005)
and  pain  reduction
(p  <  0.0001)
Napolitano et  al.
(2012)40
Series  of  cases  WOMAC
NRS
(6  months)
PRP  (27)  Improvement  in  pain  and
functions.  Signiﬁcant  pain
reduction  after  the  ﬁrst
application  (without
statistical  assessment)
Filardo G  et  al.  (2012)41 Randomised  IKDC
KOOS
VAS
(2,  6  and  12
months)
PRP  (55)  vs.  HA
(54)
Signiﬁcant  improvement  in
assessments.  No  signiﬁcant
difference  between  groups.
Better  results  in  patients
with  mild  erosion
Spaková et  al.  (2012)42 Prospective  WOMAC
NRS
(3  and  6  months)
PRP  (60)  vs.  HA
(60)
Better  results  in  clinical
evaluations  for  the  group
treated  with  PRP  (p  <  0.01)
Cerza et  al.  (2012)43 Randomised  WOMAC
(1,  3  and  6  months)
PRP  (60)  vs.  HA
(60)
Signiﬁcant  improvement  in
the  WOMAC  scale  at  the
end  of  the  study,  in
patients  treated  with  PRP
(p <  0.001)
Sanchez et  al.  (2012)44 Randomised  WOMAC
OMERACT-OARSI
(6  months)
PRP  (79)  vs.  HA
(74)
Higher  percentage  of
responders  in  PRP  group
(14.1%  more  than  HA;
p =  0.044)
Vaquerizo et  al.  (2013)45 Randomised  WOMAC
OMERACT-OARSI
Lequesne  index
(6  and  12  months)
PRP  vs.  HA  (96  in
total)
Treatment  with  PRP  was
signiﬁcantly  more  effective
and  the  respondent  range
was  signiﬁcantly  higher
than  with  HA
VAS, visual analogue scale; HA, hyaluronic acid; HW, high weight; IKDC, International Knee Documentation Committee; KOOS, knee
injury and osteoarthritis outcome score; LW, low weight; NRS, numeric rating scale; OMERACT-OARSI, Rheumatology Committee and
Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative; PRP, platelet-rich plasma;
WOMAC, Western Ontario and McMaster Universities Index of Osteoarthritis.
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ene  expression.  Their  most  common  mechanism  of  action
s  paracrine  or  autocrine,  and  occasionally  endocrine.  Thus,
he  cell  or  cells  that  receive  the  signal  may  be  near  to
r  far  from  the  cell  that  has  synthesised  and  released  this
actor.23 An  ideal  growth  factor  in  the  regeneration  of  car-
ilage  should  be  effective  regardless  of  the  patient’s  age
r  the  existence  of  osteoarthrosis  and  will  not  damage  the
artilage  or  the  synovial  membrane.
Table  124--27 shows  some  growth  factors  that  are  present
n  platelet-rich  plasma,  which  have  proven  to  be  impor-
ant  in  the  restoration  of  the  cartilage.  In  general,  these
olecules  have  anabolic  features  that  stimulate  the  syn-
hesis  of  proteoglycans,  aggrecans  and  Type  II  collagen  in
hondrocytes;  they  induce  the  proliferation  of  synoviocytes
nd  mesenchymal  stem  cells,  and  reduce  the  catabolic
ffects  of  cytokines,  such  as  the  interleukine-1  (IL-1),  and
f  the  extracellular  matrix  metalloproteases  (MMP).28
onventional treatment for knee
steoarthrosis
he  ideal  treatment  is  multidisciplinary  and  must  fulﬁl  the
bjectives  of  attaining  analgesia,  reducing  disability  and
mproving  articular  functionality,  as  well  as  improving  the
atient’s  quality  of  life  with  a  lower  level  of  toxicity  of
rugs.
Pharmacological  treatment  usually  begins  with  anal-
esics,  such  as  paracetamol  (ﬁrst-line  drug  to  handle
ain  in  osteoarthrosis),  steroidal  anti-inﬂammatory  agents,
nd  other  non-steroidal  anti-inﬂammatory  drugs.29 Drugs
ike  glucosamine,  chondroitin  sulphate,  hyaluronic  acid
viscosupplementation)  and  glucocorticoids  have  been  pro-
osed  as  non-invasive  solutions  to  treat  pain  and  improve
he  mobility  of  joints,  all  with  variable  success  rates.
hese  drugs  can  exhibit  limitations  for  their  correct
dministration,  such  as  a  potential  cardiovascular  and
astrointestinal  toxicity,  an  apparently  great  variation  in
ndividual  responses  to  each  drug,  and  the  absence  of  clear
linical  data  regarding  the  therapeutic  potential  of  these
ubstances.30 None  of  the  available  current  treatments  can
e  considered  as  an  ideal  procedure  to  treat  chronic  severe
hondropathy  or  osteoarthrosis.
latelet-rich plasma as tissue regenerative
herapy
utologous  platelet-rich  plasma  has  been  proposed  as  one
f  the  biological  therapies  that  can  have  potential  clinical
pplications,  for  its  simplicity  in  isolation  and  availability,
nd  due  to  the  absence  of  immunological  reactions  or  dis-
ase  transmission.
The  use  of  platelet-rich  plasma  became  popular  within
he  ﬁeld  of  plastic  and  maxillofacial  surgeries  in  the  1990s.31
ental  implant  surgery  with  guided  bone  regeneration  is  one
f  the  scenarios  in  which  platelet-rich  plasma  clearly  accel-
rates  ossiﬁcation  after  the  extraction  of  a  dental  piece
nd/or  around  the  titanium  implants  used.32 As  for  the  use
f  this  therapy  in  orthopaedics,  it  started  in  the  beginning  of
000s  with  the  use  of  platelet-rich  plasma  in  bone  grafts,  to
ncrease  spinal  fusion  and  fracture  consolidation.  Although
he  discussion  about  the  potential  beneﬁts  of  platelet-rich
o
e
w
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lasma  in  restoring  bone33 continues,  an  increasing  amount
f  evidence  at  trial  level  in  several  animal  models  sup-
orts  its  use  to  regenerate  soft  tissue,  such  as  tendons.34
n  the  other  hand,  in  tendon  explant  cultures,  and  of  liga-
ents  in  the  presence  of  platelet-rich  plasma,  a  reduction
n  the  expression  of  the  gene  that  codiﬁes  for  an  extracel-
ular  matrix  protease  (MMP-13)  could  be  observed,  as  well
s  an  increase  in  the  expression  of  the  cartilage  oligomeric
atrix  protein  (COMP)  gene,  which  is  part  of  the  extracel-
ular  matrix  of  the  cartilage.35
linical trials on the use of platelet-rich
lasma  as a treatment for osteoarthrosis
urrently  available  clinical  trials  in  medical  literature  sup-
ort  the  use  of  platelet-rich  plasma  to  treat  lesions  in  the
artilage  of  the  knees,  administering  it  by  means  of  intra-
rticular  injections.  In  all  them,  they  use  clinical  scales  or
ates  (WOMAC,  IKDC,  KOOS,  NRS,  among  others)  to  assess
nd  measure  the  effect  of  the  treatment.
A  summary  of  the  main  trials  is  shown  in  Table  2.3,36--45
hese  are  very  heterogeneous  trials  on  the  condition  of  the
atients  who  were  treated,  the  administration  interval  for
njections,  as  well  as  the  number  of  applications  and  the  pre-
ominance  of  short  to  mid-term  assessment  periods.  Despite
his,  it  can  be  observed  that,  in  most  cases,  platelet-rich
lasma  offers  better  results  compared  to  other  approaches
mplemented  (mainly  hyaluronic  acid).
In  six  of  these  studies,  results  are  based  on  a  series  of
ases  or  uncontrolled  comparative  trials,  which  pose  one  of
he  main  disadvantages  when  assessing  platelet-rich  plasma
s  a  therapy.  However,  this  therapeutic  approach  was  safe
n  all  of  them  and  improved  the  patients’  symptoms.
The  rest  of  the  publications  concern  more  recent  trials,
here  treatment  with  platelet-rich  plasma  is  compared  with
yaluronic  acid  treatment  in  patients  treated  randomly.  The
rst  has  better  results  than  the  second  regarding  pain  reduc-
ion,  improvement  of  joint  function  and  quality  of  life.  There
ere  no  signiﬁcant  differences  among  groups  in  just  one  of
he  trials.  Clinical  evidence  of  this  type  of  trial  is  more  rel-
vant  and  the  safety  of  the  proposed  therapy  is  conﬁrmed.
he  number  of  patients  treated  per  group  ranged  from  50  to
0.
onclusion
he  use  of  platelet-rich  plasma  directed  to  the  restoration  of
issues  in  several  medical  ﬁelds  has  increased  in  the  last  few
ears  due  to  the  numerous  positive  results  derived  from  clin-
cally  and  scientiﬁcally  based  studies  concerning  its  direct
dministration.  Nevertheless,  its  effectiveness  as  a  ther-
py  to  treat  osteoarthrosis  is  not  completely  proven.  This
s  mostly  because  initially,  clinical  evidence  came  only  from
rials  of  series  of  cases,  and  they  were  not  compared  with
ny  other  treatment  and/or  control  group;  a  small  number
f  individuals  were  treated,  or  a  heterogeneous  population
f  patients  classiﬁed  according  to  the  type  of  lesion  and/or
steoarthrosis  degree.  Randomised  trials  that  provide  rel-
vant  information  have  started  to  be  published  recently,
hich  will  help  to  elucidate  this  matter.  However,  in  gen-
ral,  clinical  trials  show  an  improvement  in  the  patients
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treated,  at  least  regarding  their  symptomatology.  What  is
completely  clear  is  that  the  use  of  platelet-rich  plasma
as  an  alternative  treatment  is  safe,  due  to  the  lack  of
reports  of  severe  adverse  events  in  the  patients  treated.
We  must  also  point  out  that  in  studies  where  diverse  joint
alteration  degrees  are  treated,  younger  patients  with  lower
degree  lesions  exhibit  the  best  results.  Thus,  we  could  point
out  that  treatment  with  platelet-rich  plasma  could  have
better  results  if  it  is  applied  as  a  preventive  treatment,
before  the  erosion  is  irreversible,  such  as  would  happen  in
patients  where  the  only  treatment  option  is  to  replace  the
knee  with  a  prosthesis.  Another  relevant  observation  is  that
when  patients  treated  with  platelet-rich  plasma  undergo
a  long-term  follow-up,  initial  improvement  progressively
decreases,  so  the  subsequent  application  could  also  be  an
option.
On  the  other  hand,  it  is  important  to  take  into  consid-
eration  the  scientiﬁc  evidence  from  in  vitro  studies  or  from
animal  model  studies,  which  show  that  the  use  of  platelet-
rich  plasma  can  reverse  the  damage  caused  in  the  injured
cartilage.  The  beneﬁts  of  the  use  of  platelet-rich  plasma
in  joints  can  be  observed  in  them,  such  as  the  reversion  of
inﬂammatory  processes  or  the  formation  of  an  extracellular
matrix.
For  now,  treatment  with  platelet-rich  plasma  must  be
reserved  for  those  patients  who,  based  on  recent  clinical
evidence,  can  show  the  best  results,  in  case  conservative
conventional  treatment  has  failed.  Future  studies  will  have
to  clarify  factors  such  as  what  is  the  best  formulation  or
which  are  the  best  administration  procedures  (number  of
applications,  interval  between  applications).
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